患者様やご家族など一般の方向け臨床・治癒情報サイト　臨床研究情報ポータルサイト

• 進捗状況
• 試験名
• 対象疾患名
• 地域
• 登録日
•  

• Recruiting

• Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
• Psoriasis;Cutaneous T Cell Lymphoma;Lymphoproliferative Disorders;Eczema;Lichen Planus;Prurigo;Pruritus;Polymorphic Light Eruption;Graft Vs Host Disease;Mastocytosis;Vitiligo;Psoriasis;Cutaneous T Cell Lymphoma;Lymphoproliferative Disorders;Eczema;Lichen Planus;Prurigo;Pruritus;Polymorphic Light Eruption;Graft Vs Host Disease;Mastocytosis;Vitiligo;Psoriasis;Cutaneous T Cell Lymphoma;Lymphoproliferative Disorders;Eczema;Lichen Planus;Prurigo;Pruritus;Polymorphic Light Eruption;Graft Vs Host Disease;Mastocytosis;Vitiligo;Psoriasis;Cutaneous T Cell Lymphoma;Lymphoproliferative Disorders;Eczema;Lichen Planus;Prurigo;Pruritus;Polymorphic Light Eruption;Graft Vs Host Disease;Mastocytosis;Vitiligo
• Austria
• 2017-10-29

• Recruiting

• Comparative bioequivalence study of a generic formulation of fingolimod capsule against the innovator fingolimod capsule in fasting healthy subjects
• Bioequivalence study conducted in healthy volunteers comparing two formulations of fingolimod with no health condition or problem studied. Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, fingolimod belongs to a class of medicines called asphingosine 1-phosphate modulators. It it used in the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
• ,Outside, New Zealand
• 2015-10-07

• Recruiting

• Network for Early Onset Cystic Kidney Diseases
• ;Q61.1 - Polycystic kidney, autosomal recessive;Q61.3 - Polycystic kidney, unspecified;Q61.8 - Other cystic kidney diseases;Q61.9 - Cystic kidney disease, unspecified;Q87.5 - Other congenital malformation syndromes with other skeletal changes;Q87.8 - Other specified congenital malformation syndromes, not elsewhere classified;Q77.2 - Short rib syndrome;Q77.6 - Chondroectodermal dysplasia;Q77.9 - Osteochondrodysplasia with defects of growth of tubular bones and spine, unspecified
• Austria, Germany, Switzerland
• 2016-09-06

• Recruiting

• Project: Every Child for Younger Patients With Cancer
• Central Nervous System Neoplasm;Childhood Immature Teratoma;Childhood Langerhans Cell Histiocytosis;Childhood Malignant Neoplasm;Childhood Mature Teratoma;Congenital Mesoblastic Nephroma;Desmoid-Type Fibromatosis;Lymphoproliferative Disorder;Myeloproliferative Neoplasm;Stromal Neoplasm
• Australia, Canada, New Zealand, Puerto Rico, Saudi Arabia, United States
• 2015-03-25

• Recruiting

• Analgesic, Sedative and Antibiotic Pharmacokinetics during Extracorporeal Membrane Oxygenation: Understanding altered pharmacokinetics to improve patient outcomes.
• Alterations to the pharmacokinetics of sedative and analgesic drugs and their metabolites (morphine - morphine 3 glucorunide, morphine 6 glucuronide, midazolam - 1 and 4 hydroxy midazolam, fentanyl - norfentanyl, dexmedetiomedine, propofol, thiopentone) in critically ill patients receiving ECMO.;Alterations to the pharmacokinetics of broad spectrum antibiotics (ceftriaxone, cefepime, meropenem, gentamicin, ciprofloxacin, ticarcillin-clavulanate, piperacillin-tazobactum, vancomycin, linezolid, caspofungin, fluconazole, voriconazole, oseltamivir/oseltamivir carboxylate) in critically ill patients receiving ECMO.
• Australia, New Zealand, Outside
• 2012-05-25